Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.GlaxoSmithKline (GSK) has partnered with Canadian biopharmaceutical firm Medicago to develop, assess and manufacture a plant-based adjuvanted Covid-19 vaccine candidate.
As part of the collaboration, GSK’s pandemic adjuvant system will be combined with Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP), which mimic the novel coronavirus’ structure and enable identification by the immune system.
An adjuvant is intended to enhance the immune response and minimise the amount of antigen required per dose, facilitating the production of more vaccine doses.